Trials / Sponsors / Shanghai Runshi Pharmaceutical Technology Co., Ltd
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Industry · 8 registered clinical trials — 6 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma Recurrent or Progressive High Grade Meningioma | Phase 2 | 2025-01-31 |
| Not Yet Recruiting | Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Unresectable Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | 2024-11-13 |
| Not Yet Recruiting | A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma Advanced Oesophageal Squamous Cell Carcinoma | Phase 3 | 2024-10-31 |
| Not Yet Recruiting | A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastr Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past | Phase 1 / Phase 2 | 2024-08-26 |
| Recruiting | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | 2024-03-15 |
| Not Yet Recruiting | A Study of Simmitinib Plus SG001 in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2024-01-30 |
| Completed | Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants Healthy Participants | Phase 1 | 2023-12-20 |
| Unknown | A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Sol Locally Advanced Unresectable Carcinoma | Phase 1 / Phase 2 | 2021-06-25 |